---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-26-000056"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2026-06-30T11:00:24+00:00"
generated_at: "2026-06-30T11:05:11.097578+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Novocure's Optune Pax receives CE Mark for locally advanced pancreatic cancer

## Summary
- CE Mark supported by Phase 3 PANOVA-3 trial showing statistically significant mOS improvement.
- mOS 16.2 vs 14.2 months (HR 0.82, p=0.039) in ITT; 18.3 vs 15.1 months in mITT.
- Time to pain progression extended 6.1 months (15.2 vs 9.1 months, HR 0.74, p=0.027).
- Optune Pax already FDA-approved Feb 2026; launch in Germany planned in coming weeks.
- Device well-tolerated; most AEs mild-moderate skin events; no new safety signals.

## SEC filing metadata
- accession: 0001645113-26-000056
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2026-06-30T11:00:24+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000056/0001645113-26-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000056/nvcr-20260630.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-26-000056
- JSON: https://secwatch.observer/filing/0001645113-26-000056.json
- Plain text: https://secwatch.observer/filing/0001645113-26-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.